This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taylor, A. J. Articles by Nissen, S. E. Search for Related Content PubMed Articles by Taylor, A. J. Articles by Nissen, S. E.

Cardiovascular Perspectives

Preliminary Observations From Preliminary Trial Results

Have We Finally Had Enough?

Allen J. Taylor, MD and Steven E. Nissen, MD

From the Cardiology Service, Walter Reed Army Medical Center, Washington, DC (A.J.T.); and the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio (S.E.N.).

Correspondence to Allen J. Taylor, MD, Walter Reed Army Medical Center, 6900 Georgia Ave NW, Building 2, Room 4A34, Washington, DC 20307-5001. E-mail allen.taylor@amedd.army.mil

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Results from the Simvastatin Ezetimibe Aortic Stenosis study (SEAS, registration No. NCT00092677) were prematurely released in a surprise announcement on July 21, 2008. In a carefully scripted media event, including a webcast from the United Kingdom, surprise findings of increased incidence of cancer and cancer death in patients treated with simvastatin-ezetimibe were disclosed and immediately dismissed as "not credible." To refute the observation of excess cancer events, the SEAS investigators offered a well-intentioned but hastily performed pooled analysis using data derived from 2 prematurely unblinded, ongoing ezetimibe outcomes trials (Study of Heart and Renal Protection [SHARP, registration No. NCT00125593] and IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT, registration No. NCT00202878]). Unrelated to the cancer findings, primary and secondary outcome data were also prematurely disclosed. The purpose of this event was no doubt to dispel cancer concerns for a "blockbuster" drug (ezetimibe) that had already been subjected to considerable criticism and scrutiny.^1,2 However, all of this occurred without any peer review of the data, which denied the medical community the opportunity to fully evaluate the benefits and risks of this drug in the usual scientific fashion.

SEAS was a 4-year, prospective, randomized trial that compared simvastatin-ezetimibe with placebo in 1873 adults with mild to moderate aortic stenosis. The primary end point of the SEAS study was "major cardiovascular events," a composite of events associated with aortic valve and atherosclerotic diseases. The secondary end points were the 2 separate components of the primary end point: "aortic valve . . . [Full Text of this Article]

This article has been cited by other articles:

				H. M. Krumholz One Year at Circulation: Cardiovascular Quality and Outcomes Circ Cardiovasc Qual Outcomes, September 1, 2009; 2(5): 399 - 401. [Full Text] [PDF]

				H. M. Krumholz Circulation: Cardiovascular Quality and Outcomes: Scholarship to Improve Health and Health Care for Patients and Populations Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 1 - 3. [Full Text] [PDF]